Literature DB >> 26071390

The incidence of Trichomonas vaginalis infection in women attending nine sexually transmitted diseases clinics in the USA.

Maria L Alcaide1, Daniel J Feaster2, Rui Duan2, Stephanie Cohen3, Chanelle Diaz4, Jose G Castro1, Matthew R Golden5, Sarah Henn6, Grant N Colfax3, Lisa R Metsch7.   

Abstract

OBJECTIVES: Trichomoniasis (TV) is associated with an increased risk of acquisition of sexually transmitted diseases (STDs) and HIV. The purpose of this study is to evaluate factors associated with incidence TV among female STD clinic attendees in the USA.
METHODS: Data were collected from women participating in a randomised controlled trial evaluating brief risk reduction counselling at the time of HIV testing to reduce sexually transmitted infections (STIs) incidence in STD clinics. Participants recruited from STD clinics underwent STI testing at baseline and 6-month follow-up. TV testing was performed using Nucleic Acid Amplification Test.
RESULTS: 1704 participants completed study assessments. Prevalence of TV was 14.6%, chlamydia 8.6%, gonorrhoea 3.0%, herpes simplex virus 2 44.7% and HIV 0.4%. Cumulative 6-month incidence of TV was 7.5%. Almost 50% of the incident TV cases had TV at baseline and had received treatment. Factors associated with incidence of TV were having chlamydia, TV and HIV at baseline: TV relative risk (RR)=3.37 (95% CI 2.35 to 4.83, p<0.001); chlamydia RR=1.92 (95% CI 1.23 to 2.99, p=0.04); and HIV=1.59 (95% CI 1.01 to 2.50, p=0.047).
CONCLUSIONS: Prevalent and incident TV is common among STD clinic attendees; and baseline TV is the main risk factor for incident TV, suggesting high rates of reinfection or treatment failures. This supports the importance of rescreening women after treatment for TV, evaluating current treatment regimens and programmes to ensure treatment of sexual partners. CLINICAL TRIAL NUMBER: NCT01154296. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  EPIDEMIOLOGY (CLINICAL); TRICHOMONAS; WOMEN

Mesh:

Year:  2015        PMID: 26071390      PMCID: PMC4874593          DOI: 10.1136/sextrans-2015-052010

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  28 in total

1.  A modified poisson regression approach to prospective studies with binary data.

Authors:  Guangyong Zou
Journal:  Am J Epidemiol       Date:  2004-04-01       Impact factor: 4.897

2.  A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women.

Authors:  Patricia Kissinger; Leandro Mena; Judy Levison; Rebecca A Clark; Megan Gatski; Harold Henderson; Norine Schmidt; Susan L Rosenthal; Leann Myers; David H Martin
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12-15       Impact factor: 3.731

3.  The prevalence of trichomoniasis in young adults in the United States.

Authors:  William C Miller; Heidi Swygard; Marcia M Hobbs; Carol A Ford; Mark S Handcock; Martina Morris; John L Schmitz; Myron S Cohen; Kathleen Mullan Harris; J Richard Udry
Journal:  Sex Transm Dis       Date:  2005-10       Impact factor: 2.830

4.  Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial.

Authors:  Jane R Schwebke; Marcia M Hobbs; Stephanie N Taylor; Arlene C Sena; Michael G Catania; Barbara S Weinbaum; Ann D Johnson; Damon K Getman; Charlotte A Gaydos
Journal:  J Clin Microbiol       Date:  2011-09-21       Impact factor: 5.948

5.  Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial.

Authors:  Lisa R Metsch; Daniel J Feaster; Lauren Gooden; Bruce R Schackman; Tim Matheson; Moupali Das; Matthew R Golden; Shannon Huffaker; Louise F Haynes; Susan Tross; C Kevin Malotte; Antoine Douaihy; P Todd Korthuis; Wayne A Duffus; Sarah Henn; Robert Bolan; Susan S Philip; Jose G Castro; Pedro C Castellon; Gayle McLaughlin; Raul N Mandler; Bernard Branson; Grant N Colfax
Journal:  JAMA       Date:  2013-10-23       Impact factor: 56.272

6.  Sexually transmitted diseases treatment guidelines, 2010.

Authors:  Kimberly A Workowski; Stuart Berman
Journal:  MMWR Recomm Rep       Date:  2010-12-17

7.  Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial.

Authors:  Patricia Kissinger; Norine Schmidt; Hamish Mohammed; Jami S Leichliter; Thomas L Gift; Bernadette Meadors; Cheryl Sanders; Thomas A Farley
Journal:  Sex Transm Dis       Date:  2006-07       Impact factor: 2.830

8.  A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women.

Authors:  Jennifer E Balkus; Barbra A Richardson; Vernon Mochache; Vrasha Chohan; Jeannie D Chan; Linnet Masese; Juma Shafi; Jeanne Marrazzo; Carey Farquhar; R Scott McClelland
Journal:  Sex Transm Dis       Date:  2013-06       Impact factor: 2.830

9.  The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004.

Authors:  Madeline Sutton; Maya Sternberg; Emilia H Koumans; Geraldine McQuillan; Stuart Berman; Lauri Markowitz
Journal:  Clin Infect Dis       Date:  2007-10-15       Impact factor: 9.079

Review 10.  Trichomoniasis: under control or undercontrolled?

Authors:  David Soper
Journal:  Am J Obstet Gynecol       Date:  2004-01       Impact factor: 8.661

View more
  3 in total

Review 1.  Enzymatic Transition States and Drug Design.

Authors:  Vern L Schramm
Journal:  Chem Rev       Date:  2018-10-18       Impact factor: 60.622

Review 2.  Clinical and Laboratory Testing for Trichomonas vaginalis Infection.

Authors:  Barbara Van Der Pol
Journal:  J Clin Microbiol       Date:  2015-10-21       Impact factor: 5.948

3.  Modelling-based evaluation of the costs, benefits and cost-effectiveness of multipathogen point-of-care tests for sexually transmitted infections in symptomatic genitourinary medicine clinic attendees.

Authors:  Susie E Huntington; Richéal M Burns; Emma Harding-Esch; Michael J Harvey; Rachel Hill-Tout; Sebastian S Fuller; Elisabeth J Adams; S Tariq Sadiq
Journal:  BMJ Open       Date:  2018-09-10       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.